Peter Attia Longevity Protocols: What Clinicians Should Tell Patients

Who Is Peter Attia and Why Are Patients Quoting Him?

Peter Attia trained as a general surgeon at Johns Hopkins and completed a surgical oncology fellowship at the National Cancer Institute before pivoting to what he calls "Medicine 3.0," a proactive, data-dense approach to extending healthspan. His podcast, "The Drive," routinely ranks in the top 10 health podcasts globally, and his 2023 book Outlive: The Science and Art of Longevity reached the New York Times bestseller list within its first week.

Patients do not arrive with vague impressions. They arrive with timestamps. "Dr. Attia said at minute 42 of episode 271 that his apoB target is under 20 mg/dL." Clinicians who have not heard the episode are immediately at a disadvantage.

Why His Influence Differs from Typical Celebrity Health Advice

Attia cites primary literature. He names trials by acronym. He reverses publicly when new data emerge, as he did with metformin in 2022. That intellectual honesty gives him credibility that, say, a supplement-brand influencer does not have, and it means patients quoting him are often quoting real science, even if the clinical translation is incomplete.

His framework groups the "four horsemen of death" (cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction) as targets for early, aggressive intervention, decades before symptoms appear. This is not fringe medicine. The ACC/AHA 2019 primary prevention guideline explicitly supports earlier, more aggressive lipid management in appropriately selected patients. [1]

Rapamycin: The Off-Label Intervention Patients Ask About Most

Rapamycin (sirolimus) is an mTOR inhibitor approved by the FDA for organ-transplant rejection prophylaxis and certain rare tumors. [2] Attia takes it off-label at a self-reported dose of approximately 6 mg once weekly, a pulsed schedule intended to inhibit mTORC1 while minimizing mTORC2 suppression.

The Animal Data Are Genuinely Impressive

The Interventions Testing Program (ITP), a multi-site NIA-funded program, showed that rapamycin extended median lifespan in genetically heterogeneous mice by 9-14% in males and 14-16% in females, even when started at a human-equivalent age of 60 years. [3] That is not a marginal result. The same program has tested over 40 compounds; very few show strong lifespan extension across multiple sites.

Human Evidence Remains Indirect

No completed RCT has tested rapamycin for lifespan extension in healthy humans. The PEARL trial (NCT04995354), a phase 2 placebo-controlled study of RTB101 (a TORC1 inhibitor) and rapamycin analogs in older adults, is among the closest attempts, focusing on immune function and biomarkers rather than mortality. [4] A 2014 Science Translational Medicine study by Mannick et al. Showed that rapalog RAD001 at 0.5 mg daily or 5 mg weekly improved influenza vaccine response in adults over 65, suggesting meaningful immune modulation at pulsed doses. [5]

What to Tell Patients About Rapamycin

Clinicians should acknowledge the mechanistic rationale without overstating clinical certainty. Known risks at immunosuppressive doses include impaired wound healing, hyperlipidemia, mouth sores, and increased infection susceptibility. [2] At the lower pulsed doses Attia describes, the side-effect profile appears attenuated, but long-term safety data in healthy adults are not available.

A reasonable clinical position: patients asking about rapamycin deserve a conversation about the genuine animal-model evidence, the absence of human RCT data, the real off-label prescribing risks, and the importance of baseline labs (CBC, CMP, fasting lipid panel) if they proceed. Dismissal without engagement sends them to less-qualified sources.

Testosterone Replacement Therapy in the Longevity Context

Attia has disclosed testosterone replacement therapy as part of his personal protocol, framing it around maintaining muscle mass, cognitive function, and metabolic efficiency as endogenous testosterone declines with age.

What the Evidence Supports

The Testosterone Trials (TTrials), a coordinated set of seven double-blind RCTs in men 65 and older with confirmed low testosterone (<275 ng/dL), showed that TRT improved sexual function, bone density, and anemia markers. [6] The cardiovascular signal was mixed: the TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not increase major adverse cardiovascular events compared with placebo in men with hypogonadism and elevated cardiovascular risk, with a hazard ratio of 0.96 (95% CI 0.78-1.17). [7]

The Age-Related Decline Question

Male testosterone declines roughly 1-2% per year after age 30. [8] Whether that decline constitutes a disease requiring treatment, or a normal physiologic shift, is a genuine clinical debate. The Endocrine Society's 2018 clinical practice guideline recommends TRT only in men with symptomatic hypogonadism confirmed on two morning testosterone measurements. [9] Attia's framing goes further, suggesting optimization above the lower bound of the normal range for healthspan purposes. That is a defensible philosophical position but not yet a guideline recommendation.

Talking Points for Patients Asking About TRT

Clinicians should check two morning total testosterone levels, LH, FSH, and SHBG before any conversation about treatment. Patients with total testosterone consistently below 300 ng/dL and symptoms (low libido, fatigue, loss of lean mass) meet guideline criteria. [9] Patients with testosterone at 450 ng/dL asking for optimization into the 900 ng/dL range are in off-label territory. The conversation should be explicit about that distinction.

Lipid Management: Attia's apoB Targeting Strategy

Attia argues that LDL-C is an imperfect proxy and that apolipoprotein B (apoB) is the superior target because each atherogenic particle carries exactly one apoB molecule. He publicly targets his own apoB below 30-40 mg/dL, and he advocates for aggressive statin therapy starting earlier in life than current guidelines suggest.

Is the apoB Argument Evidence-Based?

Yes, substantially. A 2021 JAMA Cardiology analysis of Mendelian randomization and intervention trial data concluded that apoB more completely captures atherogenic lipoprotein burden than LDL-C, particularly in patients with high triglycerides or insulin resistance. [10] The European Atherosclerosis Society consensus statement set an apoB target of <65 mg/dL for very high-risk patients, a figure meaningfully lower than typical LDL-C-translated targets. [11]

Where Attia Departs from Guidelines

His personal target of 30-40 mg/dL has no direct RCT support for that specific threshold in primary prevention. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction supports high-intensity statins for primary prevention in patients with 10-year ASCVD risk above 7.5-10%, but does not specify an apoB floor. [1] Attia's approach treats the atherosclerosis exposure as cumulative across decades, arguing that starting statin therapy at 35 instead of 55 compresses decades of plaque burden. The biology supports that hypothesis; the RCT evidence for mortality benefit in low-risk 35-year-olds does not yet.

Clinical Recommendation

Order apoB alongside the standard lipid panel for any patient asking about longevity-focused lipid management. An apoB above 90 mg/dL in a patient without other major risk factors is a clinically actionable finding even under current guidelines. The conversation about targets below 60 mg/dL should be framed as emerging evidence rather than established standard of care.

Exercise: The Intervention With the Strongest Evidence Base

Attia is emphatic that exercise is the single most potent longevity intervention available, and the evidence supports that position more comprehensively than any pharmaceutical in his stack.

Zone 2 Cardio and VO2max

A 2022 study in the Journal of the American College of Cardiology (N=122,007) found that cardiorespiratory fitness ranked as the strongest predictor of all-cause mortality, with low fitness carrying a hazard ratio for death comparable to or exceeding smoking. [12] Attia advocates for 3-4 hours of Zone 2 cardio per week (roughly 60-70% of maximum heart rate, a pace at which conversation is possible but effortful) plus one to two VO2max interval sessions weekly.

Strength and Stability

Grip strength predicts all-cause mortality independently of aerobic fitness. A meta-analysis of 42 studies (N=2,006,079) published in the British Medical Journal in 2018 found that low grip strength was associated with a 31% higher risk of all-cause mortality (HR 1.31, 95% CI 1.25-1.37). [13] Attia's emphasis on structural strength, particularly single-leg stability and posterior chain development, aligns with falls-prevention data showing that functional strength declines accelerate fracture risk in the sixth and seventh decades.

What Clinicians Can Action Immediately

Prescribe exercise specifically. "Get more exercise" is not a prescription. For a 50-year-old patient with no contraindications, a concrete starting point is 150 minutes of moderate-intensity aerobic activity per week (the 2018 Physical Activity Guidelines for Americans) with two resistance sessions. [14] Patients ready for an Attia-level protocol can progress from there with structured periodization.

Metabolic Health: CGM, Glucose Control, and the Metformin Reversal

Attia was an early advocate for continuous glucose monitoring (CGM) in non-diabetic individuals as a tool for identifying glucose excursions that standard A1C measurements miss. He also publicly used metformin before reversing that position in 2022.

CGM in Non-Diabetic Patients

CGM devices such as Dexterity's Dexcom G7 and Abbott's FreeStyle Libre 3 are cleared by the FDA for diabetes management. [15] Use in non-diabetic individuals is off-label. A 2018 study in PLOS Biology (N=57 healthy adults) found clinically significant postprandial glucose excursions above 140 mg/dL in participants with normal A1C, suggesting that standard screening misses meaningful glucose variability. [16] Whether correcting those excursions improves long-term outcomes has not been tested in an RCT.

The Metformin Position Shift

Attia dropped metformin from his protocol after the TAME (Targeting Aging with Metformin) trial design was published and after a 2022 study in Nature Aging by Konopka et al. Showed that metformin blunted mitochondrial adaptations to aerobic exercise in older adults. [17] That finding mattered to him because he prioritizes exercise as the primary intervention. Clinicians should note: metformin remains a first-line agent for type 2 diabetes management per the ADA Standards of Care. [18] The exercise-blunting concern applies specifically to the non-diabetic longevity use case, not to diabetic patients whose glycemic benefit from metformin is well-established.

Practical Guidance

For non-diabetic patients requesting metformin for longevity, the TAME trial (NCT03127592) has not yet reported primary outcomes. [19] Prescribing metformin off-label to a fit, non-diabetic patient who exercises heavily is difficult to justify given the Konopka data. For sedentary patients with metabolic risk, the calculation is different.

Omega-3 Fatty Acids and Other Supplements

Attia takes high-dose omega-3 fatty acids (EPA and DHA), typically 2-4 g/day of combined EPA/DHA, citing cardiovascular and cognitive data. He has discussed magnesium, vitamin D, and glycine in various episodes.

Omega-3 Evidence

The REDUCE-IT trial (N=8,179) showed that icosapentaenoic acid (EPA) 4 g/day as Vascepa reduced major adverse cardiovascular events by 25% (HR 0.75, 95% CI 0.68-0.83, P<0.001) in statin-treated patients with elevated triglycerides. [20] The STRENGTH trial, using a mixed EPA/DHA formulation, did not replicate that benefit, raising questions about whether the effect is EPA-specific or related to the mineral oil placebo in REDUCE-IT. [21]

Vitamin D

The VITAL trial (N=25,871) found that vitamin D3 supplementation at 2,000 IU/day did not reduce the primary endpoint of major cardiovascular events or invasive cancer, though secondary analyses suggested a reduction in cancer mortality. [22] Attia targets 25-OH vitamin D levels above 40 ng/mL. Clinicians should check baseline levels before recommending supplementation, as toxicity is possible above 150 ng/mL. [23]

Sleep: The Non-Negotiable Attia Emphasizes Most

Attia is unusually vocal about sleep as a foundational longevity lever, frequently citing Matthew Walker's work and his own use of an Oura Ring for sleep tracking. He targets 8 hours of sleep opportunity nightly and has publicly disclosed past sleep apnea treatment.

A 2019 meta-analysis in the Journal of the American Heart Association (N=1,262,767) found that both short sleep (<7 hours) and long sleep (>9 hours) were associated with increased all-cause mortality, with the lowest risk at 7-8 hours (RR for short sleep: 1.13, 95% CI 1.07-1.19). [24] The CDC estimates that 35% of U.S. Adults report sleeping fewer than 7 hours per night. [25]

Clinicians should screen for obstructive sleep apnea using the STOP-BANG questionnaire in any patient describing non-restorative sleep or excessive daytime fatigue. Untreated moderate-to-severe OSA increases cardiovascular mortality, and CPAP therapy reduces that risk. [26]

A Clinical Decision Framework for Attia-Inspired Patient Conversations

When a patient arrives citing Peter Attia, the conversation has three stages.

Stage 1: Sort by Evidence Tier

Not every intervention in Attia's stack has the same evidence quality. Clinicians can mentally sort the stack into three tiers before the appointment:

Tier 1 (strong RCT support, guideline-aligned): Exercise prescription, statin therapy for appropriately risk-stratified patients, sleep optimization, omega-3s at 4 g/day EPA for hypertriglyceridemia on statins.

Tier 2 (mechanistic rationale, indirect or preliminary human evidence): ApoB targeting below 60 mg/dL in primary prevention, CGM in non-diabetics, TRT for optimization above guideline thresholds, higher-dose vitamin D to achieve 40-60 ng/mL.

Tier 3 (compelling animal data, no human RCT confirmation): Rapamycin for longevity, metformin in non-diabetic exercisers, extreme apoB targets below 40 mg/dL.

Stage 2: Assess the Individual Patient's Risk-Benefit Profile

A 45-year-old with a strong family history of premature CAD, baseline apoB of 110 mg/dL, and a sedentary lifestyle has a very different risk-benefit calculation for early aggressive statin therapy than a 45-year-old marathon runner with apoB at 62 mg/dL asking about rapamycin.

Stage 3: Document the Shared Decision Conversation

For any off-label prescription generated by a longevity-focused conversation, document the clinical rationale, the patient's understanding of the evidence tier, and the agreed monitoring plan. Labs, follow-up intervals, and stopping rules should be explicit.

FAQ